Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Keytruda Nabs Top Slot in Japan Sales Ranking, 1st Time in 2 Years: Encise
September 7, 2023
- BMS Gets Rights to Zenas Antibody in Japan, Korea, and More Regions
September 7, 2023
- Osaka Court Bars Sawai’s Teribone Generic over Manufacturing Patents
September 6, 2023
- Sawai Poised to Respond to Generic System Reform and Raise Productivity: New President
September 5, 2023
- RaQualia’s Acid Reducer Tegoprazan Now Available in Singapore
September 5, 2023
- Nobelpharma Bags UK Approval for Hyftor
September 5, 2023
- Nucala Filed in Japan for Chronic Rhinosinusitis with Nasal Polyps: GSK
September 5, 2023
- Santen to Run Voluntary Redundancy Program Targeting Age 50 and Up
September 5, 2023
- Otsuka to Acquire Canada’s Psychedelic Specialist Mindset Pharma
September 4, 2023
- Enhertu Gets 2 More Breakthrough Therapy Tags in US: Daiichi Sankyo
September 4, 2023
- Shionogi Wins SCARDA R&D Funding for Nasal Vaccines for Flu, COVID
September 1, 2023
- Atozet Generic to Hit Japan Shelves on Sept. 1
September 1, 2023
- Ono, Twist Bio Tie Up on Antibody Discovery for Autoimmune Disorders
September 1, 2023
- 2 Amyloid PET Imaging Agents Expand Labels as Lecanemab Approval Nears
September 1, 2023
- Sobi’s PNH Drug to Hit Japan Market on Sept. 4, Taiho's FGFR Inhibitor on Sept. 7
August 31, 2023
- Novartis Rolls Out Luxturna in Japan, 2 Treatment Facilities Selected
August 31, 2023
- Sandoz Completes Acquisition of Astellas’ Antifungal Mycamine
August 31, 2023
- Toray to Kick Off Antibody PII Studies for Gastric Cancer
August 31, 2023
- Takeda Snags Japan Rights to ImmunoGen’s ADC
August 30, 2023
- Shionogi Rolls Out Flomox Fine Granules for Children in China
August 30, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…